[The effect of short-term erythropoietin therapy on selected parameters of cell mediated and humoral immunity in hemodialyzed uremic patients].
This study aimed to assess the influence of short-term therapy with recombinant human erythropoietin (rhEPO) on selected parameters of humoral and cell mediated immunity in haemodialyzed uraemic patients (HDP). In 12 HDP before, and after 1 and 3 months of rhEPO therapy the following parameters were assessed: nitroblue tetrazolium (NBT) test, NBT test after latex stimulation, number of B, T and CD4 and CD4- and CD8-positive T lymphocytes, serum concentrations of IgG, IgA and IgM. The number of granulocytes with a positive NBT test was significantly higher after 3 months of rhEPO therapy. The number of granulocytes with a positive NBT test after latex stimulation increase both after 1 and 3 months of rhEPO therapy but significantly only after 3 months of treatment. The number of CD4-positive T lymphocytes increased significantly after 3 months of rhEPO therapy, while the number of CD8-positive lymphocytes decreased significantly after 1 month of therapy. The CD4/CD8 ratio increased significantly after 3 months of rhEPO therapy. Serum IgA concentration increased significantly after 1 and 3 months, while serum IgG level only after 3 months of rhEPO therapy. From the results obtained in this study it follows that rhEPO therapy exerts a positive effect on function of both T and B lymphocytes in haemodialyzed uraemic patients.
D000328:Adult; D000917:Antibody Formation / Q000187:drug effects*; D001772:Blood Cell Count / Q000187:drug effects; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007136:Immunoglobulins / Q000097:blood; D018655:Lymphocyte Count / Q000187:drug effects; D008297:Male; D011994:Recombinant Proteins; D006435:Renal Dialysis; D012397:Rosette Formation; D014511:Uremia / Q000628:therapy*
D007136:Immunoglobulins; D011994:Recombinant Proteins; D004921:Erythropoietin
Wpływ krótkotrwałego leczenia erytropoetyna na zachowanie sie wybranych parametrów odporności komórkowozaleznej i humoralnej u hemodializowanych chorych na mocznice.